Recent Updates
Recently added Catalysts

NoV Placebo-matching Saline

Phase 2

Healthy Volunteers | Monoclonal antibody | Other |Takeda Pharmaceutical Company Limited|Last Updated: Jun 10, 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment4,748

FDA Designations

No designations recorded

Clinical trial landscape

NoV Placebo-matching Saline · 1 trial · 1 indication

Phase 2 1
NCT02669121Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in AdultsHealthy Volunteers
COMPLETED4,748 Analytics
PHASE2COMPLETED
Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults
Healthy VolunteersUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Moderate or Severe Acute Gastroenteritis (AGE) Occurring for >7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Excluding Co-infection)
Up to Day 47

Acute gastroenteritis (AGE) is a sudden inflammation or swelling in the lining of the stomach causing diarrhea and vomiting. A norovirus AGE case was defined as meeting the work-up definition plus a norovirus positive stool sample or vomitus sample confirmed by reverse transcriptase polymerase chain reaction (RT-PCR). The severity of AGE was graded by the investigator as per CTCAE criteria. AGE occurring due to NoV strains excluding co-infection with Salmonella, Shigella or Campylobacter is reported. The Norovirus strains included: GI.1, GI.7a, GII.2 and GII.4.

Secondary Endpoints

Number of Participants With Moderate or Severe AGE Occurring >7 Days After Dosing Due to Any Norovirus Strain (Excluding Co-infection)
Up to Day 47
Number of Participants With Moderate or Severe AGE Occurring >7 Days After Dosing Due to Any Norovirus Strain (Including Co-infection)
Up to Day 47
Number of Participants With Moderate or Severe AGE Occurring >7 Days After Dosing Due to GI.1 or GII.4 Norovirus Strains (Including Co-infection)
Up to Day 47
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
PlaceboPLACEBO_COMPARATORNoV placebo-matching 0.5 mL solution for injection, intramuscularly (IM), once, on Day 1.
NoV GI.1/GII.4 Bivalent VLP VaccineEXPERIMENTALNoV GI.1/GII.4 bivalent virus-like particle (VLP) vaccine, 0.5 mL injection, intramuscularly (IM), once, on Day 1.

Interventions

NameTypeDescription
NoV Placebo-matching SalineBIOLOGICALNoV placebo-matching saline (0.9% sodium chloride).
NoV GI.1/GII.4 Bivalent VLP VaccineBIOLOGICALNoV bivalent VLP vaccine, adjuvanted with 500 µg aluminum as Al(OH)3.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 49 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any trial procedures after the nature of the trial has been explained according to local regulatory requirements. 2. Male or female participants, 18 ...

Countries:United States
Unlock Eligibility Criteria